HCWB logo

HCW BIOLOGICS INC

HCWBNASDAQ
πŸ† #5137 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track HCWB
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$2M
Small Cap
πŸ“ˆRevenue Growth (YoY)
710.1%
High Growth
πŸ“ŠGross Margin
96.1%
High
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
0.4x
Cheap
Otter Score
β€”
Insufficient data
No chart data available for HCWB.

Trading Snapshot

Day Range
β€”
52-Week Range
$0.70 – $23.94
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
2.2M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$54,232
Last Q Revenue
$135,568
P/E Ratio
β€”
P/S Ratio
0.4x
EPS (TTM)
$-10.91
Dividend Yield
β€”
Dilution (1yr)
βˆ’94.6%
HCWB logo

HCW BIOLOGICS INC

HCWB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$54Kβ–Ό βˆ’97.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
20.0%β–Ό βˆ’46.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$11Mβ–Ό βˆ’61.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$13Mβ–Ό βˆ’7.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
350Kβ–Ό βˆ’94.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$5Mβ–² +$4M YoY
StockOtter Β· stockotter.space

About HCW BIOLOGICS INC

HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.